In our previous studies, SMYD3, a vital onco‐driver, was found to play crucial roles in tumorigenesis and progression in prostate cancer as well as RCC.[14] However, the effects of SMYD3 on the tumor immune microenvironment and the response of ccRCC to ICIs have not been investigated. Here, SMYD3 is linked to renal cell carcinoma.